Dan Hertz joined the Department of Clinical Pharmacy in the College of Pharmacy in April 2013. He received his PharmD from the Ernest Mario School of Pharmacy at Rutgers University and his PhD in pharmaceutical sciences from the University of North Carolina Eshelman School of Pharmacy.

Interested in developing tools for individualizing cancer treatment, his current work focuses on the optimal use of paclitaxel in breast cancer. The approaches being developed include identifying an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity, particularly as it relates to neuropathy. Hertz is also interested in understanding the influence of patient genetics on cancer treatment outcomes. He uses several approaches to discover and validate the effect of common variants on drug exposure or patient sensitivity to toxicity. Much of this work is conducted through his membership in oncology cooperative groups, which provide access to sufficiently large patient cohorts for definitive analyses. 

Research Interests

  • Developing tools for individualizing cancer treatments

  • Understanding the role of patient genetics in treatment outcomes

  • Translating genetic associations into clinical practice to improve patient care

Selected Publications

  • Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irivin Jr. WJ, In Vivo Assessment of the Metabolic Activity of CYP2D6 Diplotypes and Alleles. Br J Clin Pharmacol. 2015 Apr 24. doi: 10.1111/bcp.12665. [Epub ahead of print] PMID: 25907378 (In Press)

  • McWhinney-Glass S*, Winham SJ*, Hertz DL, Yen-Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, and McLeod HL, Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity, Clin Cancer Res 2013 Oct 15;19(20):5769-76 doi:10.1158/1078-0432.CCR-13.0774 PMID: 23963862,  PMCID: PMC3798385

  • Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013 Jun;24(6):1472-8. PMID: 23413280, PMCID: PMC3660078

  • Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012 Jul;134(1):401-10. PMID: 22527101, PMCID: PMC3727245

  • Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC. Pilot Study of Rosiglitazone as an in vivo Probe of Paclitaxel Exposure, Br J Clin Pharmacol. 2012 Jul;74(1):197-200. PMID: 22680343, PMCID: PMC3394145

Recent Publications

  • Daniel L. Hertz; Kouros Owzar; Sherrie Lessans; Claudia Wing; Chen Jiang; William Kevin Kelly; Jai Patel; Susan Halabi; Yoichi Furukawa; Heather E. Wheeler; Alexander B. Sibley; Cameron Lassiter; Lois Weisman; Dorothy Watson; Stefanie D. Krens; Flora Mulkey; Cynthia L. Renn; Eric J. Small; Phillip G. Febbo; Ivo Shterev; Deanna L. Kroetz; Paula N. Friedman; John F. Mahoney; Michael A. Carducci; Michael J. Kelley; Yusuke Nakamura; Michiaki Kubo; Susan G. Dorsey; M. Eileen Dolan; Michael J. Morris; Mark J. Ratain; Howard L. McLeod Pharmacogenetic discovery in CALGB (alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clinical Cancer Research. 2016;22(19):4890-4900
  • D. L. Hertz; K. M. Kidwell; N. J. Seewald; C. L. Gersch; Z. Desta; D. A. Flockhart; A. M. Storniolo; V. Stearns; T. C. Skaar; D. F. Hayes; N. L. Henry; J. M. Rae Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics Journal. 2016;():
  • Daniel L. Hertz; Megan V. Caram; Kelley M. Kidwell; Jacklyn N. Thibert; Christina Gersch; Nicholas J. Seewald; Jeffrey Smerage; Melvyn Rubenfire; N. Lynn Henry; Kathleen A. Cooney; Monika Leja; Jennifer J. Griggs; James M. Rae Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016;17(3):231-240
  • D. L. Hertz; H. L. McLeod Integrated patient and tumor genetic testing for individualized cancer therapy. Clinical Pharmacology and Therapeutics. 2016;99(2):143-146
  • Daniel L. Hertz; N. Lynn Henry; Kelley M. Kidwell; Dafydd Thomas; Audrey Goddard; Faouzi Azzouz; Kelly Speth; Lang Li; Mousumi Banerjee; Jacklyn N. Thibert; Celina G. Kleer; Vered Stearns; Daniel F. Hayes; Todd C. Skaar; James M. Rae ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiological Genomics. 2016;48(9):688-698